ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics , Inc. (AgeX: NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported financial and operating results for the first quarter ended March 31, 2020.
The human tragedy of this pandemic has long tentacles that effect numerous businesses including AgeX, said Greg Bailey M.D., Chairman. Given the current global economic landscape, and the changes that businesses will need to make to accommodate to a post pandemic world, we feel that new business model aligns well to be able to function in this new environment. We see enormous opportunity to license and joint venture PureStem and HLA-G while implementing a definitive plan to begin preclinical trials on tissue regeneration under the leadership of Michael West and Michael May. We will update you in the future as these plans progress.
AgeX has completed a company restructuring to help set it up for success in the future. The combination of company priorities, cash position and the COVID-19 pandemic led to employee lay-offs designed to support the evolution of AgeX's current team to execute on strategic business goals going forward and to ensure cash is directed at near-term priorities to deliver maximum shareholder value. AgeX has a dual business strategy to diversify risk and maximize opportunities. It plans to continue to pursue its licensing and collaboration strategy for its two primary technology platforms, UniverCyte immunotolerance technology for the generation of universal cells, and PureStem cell derivation and manufacturing technology for the production of therapeutic cells with potential advantages, including industrial scalability and lower manufacturing costs. Since the launch of its licensing and collaboration strategy in January 2020, AgeX has delivered a research collaboration in Japan focused on developing universally transplantable cells for therapeutic use based on UniverCyte, entered into a neural stem cell therapy research collaboration for neurological disorders utilizing PureStem at a California University, and AgeX licensee ImStem Biotechnology received the first-ever clearance of a cell therapy derived from AgeXs embryonic stem cells by the FDA to enter human studies.
In addition, AgeX remains committed to pursuing in-house cell therapy product development and plans to raise money to build the optimal team to deliver on its products, AGEX-BAT1 for metabolic diseases such as type II diabetes and AGEX-VASC1 for tissue ischaemia. AgeXs budgetary and personnel adjustments will result in the deferral of in-house product development and may also lead to AgeX seeking arrangements with other companies in the cell therapy or biopharma industry for the development of its product candidates and technology, or outsourcing of some of that work to service providers until further funding can be obtained to rebuild in-house research and development staff for one or more of those programs. Development of AgeXs iTR technology may be done at AgeXs subsidiary Reverse Bioengineering, Inc. subject to successful financing of the subsidiary.
Upwards of 80% of healthcare expenditures in the United States relates to chronic degenerative disease and aging is a principle underlying cause of such conditions, said Michael D. West, Ph.D., AgeXs Chief Executive Officer. Therefore, the ability to manufacture to scale young clinical-grade cells capable of regenerating functionality in diverse tissues of the body has the potential to transform healthcare as we know it today. Perhaps even more noteworthy is the potential of reversing developmental aging in the body itself through AgeXs iTR technology. Our goal in the coming year is to advance the development of our intellectual property with the goal of bringing value to our shareholders.
Q1 Highlights
Liquidity and Capital Resources
AgeX is in need of additional capital to finance its operations. On March 30, 2020, AgeX entered into a Secured Convertible Facility Agreement (the New Loan Agreement) with Juvenescence Limited pursuant to which AgeX may borrow funds from time to time. On April 1, 2020 AgeX drew the initial $500,000, and may draw additional funds from time to time subject to Juvenescences discretion, prior to the contractual repayment date on March 30, 2023. AgeX may not draw down more than $1 million in any single draw. More information about the New Loan Agreement can be found in AgeXs Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on March 30, 2020 and May 14, 2020, respectively.
On April 13, 2020, AgeX obtained a loan in the amount of $432,952 from Axos Bank under the Paycheck Protection Program (the PPP Loan). The PPP Loan will bear interest at a rate of 1% per annum. No payments will be due on the PPP Loan during a six month deferral period commencing on the date of the promissory note. Commencing one month after the expiration of the deferral period, and continuing on the same day of each month thereafter until the maturity date of the PPP Loan, monthly payments of principal and interest will be due, in an amount required to fully amortize the principal amount outstanding on the PPP Loan by the maturity date. The maturity date is April 13, 2022. The principal amount of the PPP Loan is subject to forgiveness under the PPP to the extent that PPP Loan proceeds are used to pay expense permitted by the PPP, including payroll, rent, and utilities (collectively, Qualifying Expenses), during the time frame permitted by the PPP. AgeX intends to use the PPP Loan amount for Qualifying Expenses. However, no assurance is provided that AgeX will obtain forgiveness of the PPP Loan in whole or in part.
Staff Reductions
During April 2020, AgeX initiated staff layoffs that affected 12 employees, primarily research and development personnel. AgeX has paid approximately $105,000 in accrued payroll and unused paid time off and other benefits and expects to recognize approximately $194,800 in restructuring charges in connection with the reduction in staffing, consisting of contractual severance and other employee termination benefits, substantially all of which are expected to be settled in cash. The staff reductions followed AgeXs strategic review of its operations, giving consideration to the status of its product development programs, human resources, capital needs and resources, and current conditions in the capital markets resulting from the COVID-19 pandemic.
Going Concern Considerations
As required under Accounting Standards Update 2014-15, Presentation of Financial Statements-Going Concern (ASC 205-40), AgeX evaluates whether conditions and/or events raise substantial doubt about its ability to meet its future financial obligations as they become due within one year after the date its financial statements are issued. Based on AgeXs most recent projected cash flows, and considering that loans from Juvenescence in excess of an initial $500,000 advance under the New Loan Agreement will be subject to Juvenescences discretion, AgeX believes that its cash and cash equivalents, the $500,000 loan under the New Loan Agreement, the PPP Loan and reduction in staff in May 2020 would not be sufficient to satisfy its anticipated operating and other funding requirements for the twelve months following the filing of AgeXs Quarterly Report on Form 10-Q for the three months ended March 31, 2020. These factors raise substantial doubt regarding the ability of AgeX to continue as a going concern.
First Quarter 2020 Operating Results
Revenues: Total Revenues for the first quarter of 2020 were $515,000 as compared with $388,000 for the first quarter of 2019. AgeX revenue is primarily generated from subscription and advertising revenues from the GeneCards online database through its subsidiary LifeMap Sciences, Inc. Revenues in 2020 also included approximately $86,000 of allowable expenses under its research grant from the NIH as compared with $15,000 in the same period in 2019.
Operating expenses: Operating expenses reported for the three months ended March 31, 2020 were $3.7 million as compared to $3.4 million for the same period in 2019. On an as-adjusted basis, operating expenses for the three months ended March 31, 2020 were $3.2 million as compared to $2.8 million for the same period in 2019.
The reconciliation between GAAP and non-GAAP operating expenses is provided in the financial tables included with this earnings release.
Research and development expenses increased by $0.3 million to $1.6 million during the three months ended March 31, 2020 from $1.3 million during the same period in 2019. The increase was primarily attributable to an increase of $0.2 million in scientific consultants, $0.2 million in laboratory facilities and equipment related expenses and maintenance, $0.1 million in personnel related expenses allocable to research and development, and $0.1 million in depreciation and amortization of laboratory equipment and improvements. These increases were offset to some extent by a decrease of $0.3 million in shared services from Lineage Cell Therapeutics, Inc. (Lineage) with the termination of the Shared Facilities and Services Agreement on September 30, 2019.
General and administrative expenses for the three months ended March 31, 2020 remained consistent with the same period in 2019 of $2.1 million despite bearing the full lease and facilities related costs since April 2019, and an increase in head count with the employment of AgeXs own finance team since October 1, 2019. These increases were offset by a decrease in shared facilities and services fees from Lineage following the termination of the Shared Facilities and Services Agreement on September 30, 2019.
About AgeX Therapeutics
AgeX Therapeutics, Inc. (NYSE American: AGE) is focused on developing and commercializing innovative therapeutics for human aging. Its PureStem and UniverCyte manufacturing and immunotolerance technologies are designed to work together to generate highly defined, universal, allogeneic, off-the-shelf pluripotent stem cell-derived young cells of any type for application in a variety of diseases with a high unmet medical need. AgeX has two preclinical cell therapy programs: AGEX-VASC1 (vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells) for Type II diabetes. AgeXs revolutionary longevity platform induced Tissue Regeneration (iTR) aims to unlock cellular immortality and regenerative capacity to reverse age-related changes within tissues. AGEX-iTR1547 is an iTR-based formulation in preclinical development. HyStem is AgeXs delivery technology to stably engraft PureStem cell therapies in the body. AgeXs core product pipeline is intended to extend human healthspan. AgeX is seeking opportunities to establish licensing and collaboration arrangements around its broad IP estate and proprietary technology platforms and therapy product candidates.
For more information, please visit http://www.agexinc.com or connect with the company on Twitter, LinkedIn, Facebook, and YouTube.
Forward-Looking Statements
Certain statements contained in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not historical fact including, but not limited to statements that contain words such as will, believes, plans, anticipates, expects, estimates should also be considered forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of AgeX Therapeutics, Inc. and its subsidiaries, particularly those mentioned in the cautionary statements found in more detail in the Risk Factors section of AgeXs most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commissions (copies of which may be obtained at http://www.sec.gov). Subsequent events and developments may cause these forward-looking statements to change. AgeX specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law.
AGEX THERAPEUTICS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(IN THOUSANDS, EXCEPT PAR VALUE AMOUNTS)
March 31,
2020
December 31,
2019
(Unaudited)
ASSETS
CURRENT ASSETS
Cash and cash equivalents
$
468
$
2,352
Accounts and grants receivable, net
366
363
Prepaid expenses and other current assets
1,238
1,339
Total current assets
2,072
4,054
Go here to read the rest:
AgeX Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Update - Business Wire
- How dogs are paving the way for human longevity drugs - Longevity.Technology - April 12th, 2024 [April 12th, 2024]
- Innovative Approaches to Improving Human Longevity - Securities.io - April 12th, 2024 [April 12th, 2024]
- Top 5 Companies Offering Solutions to Increased Human Longevity - Securities.io - April 12th, 2024 [April 12th, 2024]
- Morning Medical Update: Gut bacteria and longevity; People with ... - Medical Economics - June 12th, 2023 [June 12th, 2023]
- Artificial Intelligence and the Aging Process: A Match Made for ... - Down to Game - June 12th, 2023 [June 12th, 2023]
- Saint Bernard Lifespan: How Long Do Saint Bernards Live? - AZ Animals - June 12th, 2023 [June 12th, 2023]
- 'Human Resources' Was Poised to Be Netflix's Longest-Running ... - PRIMETIMER - June 12th, 2023 [June 12th, 2023]
- Early Life Adversity Doesn't Affect Gorillas Like Other Species - The Good Men Project - June 12th, 2023 [June 12th, 2023]
- Wellness luminaries, experts to meet in KK - The Borneo Post - June 12th, 2023 [June 12th, 2023]
- I grew up with hazardous smoke from forest fires in Asia. Here's what ... - Morningstar - June 12th, 2023 [June 12th, 2023]
- Workplace Networks Are More Important than Promotions to Engage ... - GlobeNewswire - June 12th, 2023 [June 12th, 2023]
- Accenture staff working at Google training AI move to unionise - The Australian Financial Review - June 12th, 2023 [June 12th, 2023]
- Hair Wigs and Extension Market Size to Grow by USD 5.26 billion from 2021 to 2026, Growth Driven by Technologi - Black Enterprise - April 10th, 2023 [April 10th, 2023]
- Want to age like a fine wine? Here are some tips for longevity and feeling younger - The Indian Express - February 18th, 2023 [February 18th, 2023]
- Human body | Organs, Systems, Structure, Diagram, & Facts - January 27th, 2023 [January 27th, 2023]
- Human | Avatar Wiki | Fandom - January 27th, 2023 [January 27th, 2023]
- Calorie Restriction and Fasting Diets: What Do We Know? - January 4th, 2023 [January 4th, 2023]
- Emma Thompson On Longevity Of Holiday Fave Love Actually But It Is SEX Actually That Is Earning Her Awards Buzz In Leo Grande - Deadline - December 26th, 2022 [December 26th, 2022]
- Heads or tails: What statistical models tell us about the probability of living beyond 110 - The Conversation - December 12th, 2022 [December 12th, 2022]
- LinkedIn founder and VC Reid Hoffman says human amplification via A.I. will revolutionize large enterprises in the next five years - Fortune - December 12th, 2022 [December 12th, 2022]
- Human hibernation is possible and could boost longevity | New Scientist - December 2nd, 2022 [December 2nd, 2022]
- Home - Human Longevity Institute - October 23rd, 2022 [October 23rd, 2022]
- Exercise: 7 benefits of regular physical activity - Mayo Clinic - October 23rd, 2022 [October 23rd, 2022]
- Life expectancy - Wikipedia - October 13th, 2022 [October 13th, 2022]
- Life Expectancy - Our World in Data - October 13th, 2022 [October 13th, 2022]
- The Longevity Investors Conference Gstaad brought together longevity experts and deep-pocketed investors - Cointelegraph - October 13th, 2022 [October 13th, 2022]
- The Search for a Pill That Can Help Dogsand HumansLive Longer - WIRED - October 13th, 2022 [October 13th, 2022]
- Aging of the Heart Correlates With a Poor Gut Microbiome - Lifespan.io News - October 13th, 2022 [October 13th, 2022]
- Aditxt, Inc. (Nasdaq: ADTX) Announces Development and Publication of a Mathematical Model for Predicting Longevity and Variations of Immune Response... - October 13th, 2022 [October 13th, 2022]
- FOXO Technologies Announces First Distribution Partner and Begins Product Rollout in California; Expands Executive Team With Insurance Industry Talent... - October 13th, 2022 [October 13th, 2022]
- A conversation with Holocaust scholar Dr. Irving Berkowitz - South Florida Sun Sentinel - October 13th, 2022 [October 13th, 2022]
- Nine postdoctoral fellowships in aging research awarded by the Glenn Foundation for Medical Research and AFAR - EurekAlert - October 13th, 2022 [October 13th, 2022]
- The 5 Wellness Habits That Slow Down Aging, Science Reveals Eat This Not That - Eat This, Not That - October 13th, 2022 [October 13th, 2022]
- Winning Federal Contracts on the Top 20 Contract Vehicles - Bloomberg Government - October 13th, 2022 [October 13th, 2022]
- Lawrence Austin promoted to rank of colonel - Winona Times - October 13th, 2022 [October 13th, 2022]
- The longevity dividend: Work in an era of 100-year lives - October 2nd, 2022 [October 2nd, 2022]
- Retirement Savings Calculator - Northwestern Mutual - October 2nd, 2022 [October 2nd, 2022]
- Clues to Human Longevity Unearthed in Largescale Mouse Genetic Study - Genetic Engineering & Biotechnology News - October 2nd, 2022 [October 2nd, 2022]
- Can we find ways to live beyond 100? Millionaires are betting on it. - MIT Technology Review - October 2nd, 2022 [October 2nd, 2022]
- Restrict Calories to Boost Immune Function - The Epoch Times - October 2nd, 2022 [October 2nd, 2022]
- The Black Progress Index: Examining the social factors that influence Black well-being - Brookings Institution - October 2nd, 2022 [October 2nd, 2022]
- Kevin Williamson on Scream 6 and Franchise Longevity - Bleeding Cool News - October 2nd, 2022 [October 2nd, 2022]
- 507-Year-Old Clam May Be the World's Oldest Living Being - History of Yesterday - October 2nd, 2022 [October 2nd, 2022]
- I should look forward to early retirement, but I think I'm dreading it - CBC.ca - October 2nd, 2022 [October 2nd, 2022]
- International Coffee Day 2022: How The Beloved Brew Helps Fight Cancer, Kidney Disease And Depression - ABP Live - October 2nd, 2022 [October 2nd, 2022]
- Corey Feldman And Jamison Newlander Talk The Lost Boys And The Birth Of The Two Coreys - Forbes - October 2nd, 2022 [October 2nd, 2022]
- Proven Levels of Human Longevity | NextBigFuture.com - September 11th, 2022 [September 11th, 2022]
- Prolonging healthspan by delaying ageing -- NUHS opens Singapore's first Centre for Healthy Longevity to increase healthy lifespan of Singapore... - September 11th, 2022 [September 11th, 2022]
- What is the Secret to Longevity in Real Estate? - CandysDirt.com - Candy's Dirt - September 11th, 2022 [September 11th, 2022]
- Jeff Stukey & Jay Olshansky, Ph.D with Wealthspan Advisors, Interviewed on the Influential Entrepreneurs Podcast Discussing How Aging Science... - September 11th, 2022 [September 11th, 2022]
- The Queen of the World - The Atlantic - September 11th, 2022 [September 11th, 2022]
- THR Icon: At 100, Norman Lear Looks Back (And Ahead) at Whats Changed Since the Maude Abortion Episode - Hollywood Reporter - September 11th, 2022 [September 11th, 2022]
- TIFF 2022: The Colour of Ink Review - ThatShelf.com - September 11th, 2022 [September 11th, 2022]
- Should Age Be on the Ballot? - Next Avenue - September 11th, 2022 [September 11th, 2022]
- Was The Spring Water At Balmoral Castle The Secret To Elizabeth II's Longevity? - Nation World News - September 11th, 2022 [September 11th, 2022]
- A complete guide to the health benefits of nuts europeantimes.news - The European Times - September 11th, 2022 [September 11th, 2022]
- Debut Launches its Bio2Consumer Platform to Become the Leader in Vertically Integrated Synthetic Biology - PR Web - September 11th, 2022 [September 11th, 2022]
- Rapamycin Drug Used in Cancer Therapy Found to Increase Human Lifespan [Study] - Nature World News - August 30th, 2022 [August 30th, 2022]
- Eating Healthy: Why Eating Grapes Would Increase Lifespan | The Guardian Nigeria News - Nigeria and World News Guardian Life The Guardian Nigeria... - August 30th, 2022 [August 30th, 2022]
- Beauty Bets on Longevity WWD - WWD - August 30th, 2022 [August 30th, 2022]
- Analysis of the impact of success on three dimensions of sustainability in 173 countries | Scientific Reports - Nature.com - August 30th, 2022 [August 30th, 2022]
- You might have glowing skin in no time by making few easy changes to your skincare routine - TDPel Media - August 30th, 2022 [August 30th, 2022]
- Nucleai Appoints New Head of Pathology to Support Expansion in Biopharmaceutical and Clinical Markets - Business Wire - August 8th, 2022 [August 8th, 2022]
- Daily AI Roundup: Biggest Machine Learning, Robotic And Automation Updates - AiThority - August 8th, 2022 [August 8th, 2022]
- Prolonged and intense heatwave affecting parts of western and northern Europe breaks temperature records; globally, July 2022 was one of three warmest... - August 8th, 2022 [August 8th, 2022]
- YLEM: Augmenting sustainable futures through material exploration and testing - STIRworld - August 8th, 2022 [August 8th, 2022]
- Do you want to live forever? Big Tech and the quest for eternal youth - The New Statesman - August 6th, 2022 [August 6th, 2022]
- This startup wants to copy you into an embryo for organ harvesting - MIT Technology Review - August 6th, 2022 [August 6th, 2022]
- Renewal Bio Acquires Breakthrough Stem Cell Technology With Applications in Infertility and Longevity - Benzinga - August 6th, 2022 [August 6th, 2022]
- Get married or get a degree to live longer says study, debunking theories of womens longevity over men - Times Now - August 6th, 2022 [August 6th, 2022]
- Nucleai Appoints New Head of Pathology to Support Expansion in Biopharmaceutical and Clinical Markets - StreetInsider.com - August 6th, 2022 [August 6th, 2022]
- Some species are immortal but dying of old age is humanity's secret weapon - The Telegraph - August 6th, 2022 [August 6th, 2022]
- Opinion: Changing When and How Much We Eat May Extend Health Span - The Scientist - August 6th, 2022 [August 6th, 2022]
- Vieroots uses genome testing to win over a growing tribe of wellness enthusiasts - YourStory - August 6th, 2022 [August 6th, 2022]
- Herbs radiate and give you youthful skin - The Hans India - August 6th, 2022 [August 6th, 2022]
- How Pop Culture, Politics, Science, and Business Got So Old - The Atlantic - August 6th, 2022 [August 6th, 2022]
- John Hood: How to read this column | Columnists | journalnow.com - Winston-Salem Journal - August 6th, 2022 [August 6th, 2022]
- How Long Is The Human Lifespan? Here's What Studies Have Found | mindbodygreen - mindbodygreen - July 31st, 2022 [July 31st, 2022]
- Employees are livingand workinglonger. CEOs are introducing initiatives like phased retirements to harness the longevity economy - Fortune - July 31st, 2022 [July 31st, 2022]
- Why Do We Get Old, and Can Aging Be Reversed? - Quanta Magazine - July 31st, 2022 [July 31st, 2022]